Clinical Trial Update: A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of two doses of bivalent rLP2086 (Trumenba) and a pentavalent meningococcal vaccine in healthy individuals age…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Trumenba (rLP2086)
• pentavalent meningococcal vaccine

Snippet

Sponsor: Pfizer | Conditions: Meningococcal Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2023-08-08